Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT2219 in Relapsed/Refractory B-lineage Leukemia or Lymphoma
NCT02370160Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Dec 2015
- Primary completion
- Apr 2018
- Modality
- Bacterial Toxin Conjugates, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of DT2219ARL in B-cell leukemia (BCL), B-cell non-Hodgkin lymphoma, sponsored by Masonic Cancer Center. Started Dec 2015; status: completed.
02
Drugs
DT2219ARL
03
Conditions
B-cell leukemia (BCL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02370160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370160.